TABLE 1.
Characteristics of Study Participants
| Patient | Disease | HCT Donor | NK Donor | Age (y) | Karyotype | Pre-treatment blasts | Time to relapse (m) | Time relapse to NK infusion (m) | Acute GVHD (grade) | Therapy for post HCT relapse |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MDS | Matched sib | Child | 53.8 | del 20q | 0% | 93.6 | 58.0 | None | DLI, azacitidine |
| 2 | AML | Matched sib | Sibling | 55.9 | del 20q | 0% | 33.2 | 10.0 | Skin (2) | Surgical resection |
| 3 | MPAL* | Matched sib | Parent | 29.7 | Complex | 1% | 5.2 | 1.3 | None | Chemotherapy |
| 4 | AML | Matched Sib | Parent | 8.4 | t(9;11), del 20q | 75% | 2.4 | 1.5 | Skin (2) | Chemotherapy |
| 5 | AML | Matched sib | Parent | 2.0 | t(1;5), +20q | 21% | 3.1 | 5.6 | None | Chemotherapy |
| 6 | AML | Matched sib | Parent | 1.9 | t(9p;12p) | 23% | 3.0 | 4.2 | None | Chemotherapy |
| 7 | AML | Matched sib | Parent | 2.5 | t(3q;11p) | 71% | 3.8 | 2.7 | None | Chemotherapy |
| 8 | MDS | URD | Sibling | 32.3 | Complex | 8% | 1.0 | 4.3 | None | None |
*
Mixed phenotype acute leukemia